Tag: Januvia

Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes

by Anna Smith | Sep 19, 2019 | News | 0

Type II diabetes costs the NHS £8.8 billion a year.

Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction

by Selina McKee | Jun 29, 2018 | News | 0

Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.

US green light for Pfizer/Merck diabetes therapies

by Selina McKee | Jan 2, 2018 | News | 0

Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.

FDA rejects CV outcomes claim for Merck diabetes drugs

by Selina McKee | Apr 10, 2017 | News | 0

The US Food and Drug Administration has dealt Merck & Co a blow in turning down its request to have cardiovascular outcomes data added to the labels of its diabetes drugs Januvia and Janumet.